Idorsia's share price dropped 2.64% to EUR 1.604 on October 2, 2024, amid ongoing financial difficulties, including a negative price/earnings ratio of -0.93 and a net loss of EUR 300 million last year. With a market capitalization of EUR 303.2 million, investor concerns are mounting as they await the quarterly report on October 20, which may provide insights into the company's four drug candidates in clinical phase 3.